Clinical Trials Directory

Trials / Completed

CompletedNCT00804895

Cluster Headache Cortivazol Injection (CHCI)

A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

the aim of tis study is to demonstrate the efficacy of cortivazol injections at the level of the greater occipital nerve to diminish the frequency of cluster headache (episodic or chronic) attacks during an active period. Injections will be used in adjunct with oral verapamil.

Detailed description

Cluster headache is characterized by unilateral attacks of severe periorbital pain accompanied by autonomic symptoms and restlessness. Though patients may respond to the standard prophylactic treatment of verapamil, some are refractory and continue to suffer from numerous attacks, with a limit of two doses of subcutaneous sumatriptan per day. Some patients also have contra-indications to standard prophylactic or acute treatments. Other preventive treatments like systemic steroids, lithium and methysergide may cause significant side effects. We intend to show the efficacy of occipital nerve injections with cortivazol, in adjunct to verapamil, in cluster headache patients. We expect a diminution of attack frequency over two weeks, with a protocol of three injections separated by two or three days each. Tolerance and safety will be examined.

Conditions

Interventions

TypeNameDescription
DRUGALTIM, cortivazol injectionsALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
DRUGPROAMP, subcutaneous serum physiological salineThree injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
DRUGVerapamilstandard prophylactic treatment

Timeline

Start date
2008-12-01
Primary completion
2009-10-01
Completion
2009-10-01
First posted
2008-12-09
Last updated
2012-11-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00804895. Inclusion in this directory is not an endorsement.